Prestigious Medical Journal Publishes Article which Supports Potential New Market for VMS™

VentriPoint Diagnostics Ltd
VPT - TSX Venture
Shares issued: - 102.6 million
Fully diluted: - 134.0 million
*****************************

VentriPoint Diagnostics released news today that independent studies are expanding their product market capabilities.

The VMS™ 3D heart imaging diagnostics system has always been touted as having a broad application among variant heart diseases. Systemic Right Ventricular was the first application chosen by Dr. Shelby Kutty as he sees the simplicity of the VMS™ tool being used for continuous assessment as a therapeutic tool.

Assessment of systemic right ventricular (RV) function is a key point in the follow-up of patients. Current echocardiographic assessment of RV function is at best an estimate, and cardiac magnetic resonance (CMR) is considered the gold standard. However, in management’s view, this technique is expensive, has limited availability, and requires significant expertise to acquire and interpret the images. The VMS™ system for assessment of pulmonary RV function shows promise as a simple yet powerful tool for assessing patients with RV dysfunction of various origins.

We asked the company what the size of this market is?

The response was that singularly (i.e. per patient) this area is a much larger market than blue baby syndrome. However, the key item is the fact that the system would be used on an ongoing basis as it would monitor the success or failure of treatment as treatment usually takes years. The company’s CEO, George Adams comments on this and says: “Note that 47% of patients die from heart failure even with pacemakers. They need more intensive monitoring throughout their life and MRI is too expensive. Existing 3D ultrasound does not have a high enough resolution or window size to be useful when they are dilated and going downhill. VMS™ is perfect to monitor these patients.”

One other point which Dr. Adams comments on is:

“It is interesting that one of the limiting problems in all these studies is the resistance by the patients to undergo another MRI. Basically people hate them and try to avoid them. Since we always have to show the VMS™ is equivalent to MRI, this makes recruiting patients a challenge. Dr. Kutty was very good at talking people into participating. This absolutely reinforces our fundamental value proposition that VMS™ will be better received by the patients and doctors than MRI.”

VentriPoint is clearly on track to proving its Diagnostic promise of better patient health care.... economically.

To view today's news release, please click here.......